LG H&HLG생활건강
051900 · KOSPI · ₩051900 · LG생활건강
Analyst target price
Average target
₩330,000
Upside
+27.4%
Range ₩310,000 – ₩350,000 · 2 brokers (latest target within 6 months)
Buy 1
Consensus target vs price, 2 years
Broker reports
| Date | Broker | Report | Rating | Target | Change | Upside | Since publish | Read |
|---|---|---|---|---|---|---|---|---|
| Sep 29 | Kyobo Securities | A Breather in Q3 | Buy | ₩310,000 | New | +19.7% | −7.5% | Read ↗ |
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
Reported in the news
| Date | Broker | Target | Change | Rating | Source |
|---|---|---|---|---|---|
| Oct 26 | Sangsangin Investment & Securities | ₩350,000 | Raised | — | Reported by Edaily |
| Oct 26 | Sangsangin Investment & Securities | ₩350,000 | Raised | — | Reported by Edaily |
Target prices and ratings as news headlines report them, for every broker, including the ones whose reports we don't collect. Only what the headline says; open the article for the rest. Not financial advice.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
LG H&H remains loss-making on a trailing basis after a weak 2025, with shares well below their 52-week high.
LG H&H, a Korean cosmetics, household goods and beverage group, reported a trailing twelve-month net loss of ₩75.5B on ₩6.29T revenue through H1 2026, with a thin 2.9% operating margin. Its 2025 full-year net loss of ₩100.1B followed profits in 2024 and 2023, and revenue has fallen for several years. The shares closed at ₩257,500, about 23% below their 52-week high of ₩335,500.
What stands out
- Revenue has declined from ₩8.09T in 2021 to ₩6.29T trailing, while operating income fell from ₩1.29T to ₩184B over the same period.
- The company holds ₩1.33T in cash against ₩77B in borrowings, and trailing free cash flow is ₩440B, so the balance sheet looks conservative.
- Trailing P/B is 0.7 and EV/EBITDA is 6.9, but P/E is not meaningful because earnings are negative.
- Foreign ownership rose to 31.8% from 29.6% over about 60 days, while 20-day flows show retail and foreign investors net sellers and institutions net buyers.
- A news item dated 27 October 2026 cites a target price of ₩350,000 from one broker; this is a third-party view and not a forecast from this summary.
What to watch
- The advance notice of earnings results was filed on 20 October 2026, so the full quarterly results are the next key test of whether the operating margin is recovering.
- Filings from August and September 2026 include a rights offering (paid-in capital increase) decision and share acquisition and sale transactions in other companies; the data does not explain their size or purpose.
- The data does not give details of the risks named in the filings, so check the full filings for risk disclosures.
Data as of Oct 26, 2026 · written 2d ago
This is not financial advice.
Also known as: LG H&H / LG생활건강 / 051900 / KRX:051900
Source: KRX statistical information